Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07505303 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

StatusActive, Not Recruiting
PhasePhase 2
SponsorEccogene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting Primary and study completion moved earlier from Nov 20, 2026 to Oct 15, 2026 · Enrollment target: estimated 160 to confirmed 151 · Start date changed from estimate of Mar 13, 2026 to Mar 23, 2026v2 Show 3 more changesShow less
    • Primary and study completion moved earlier from Nov 20, 2026 to Oct 15, 2026
    • Enrollment target: estimated 160 to confirmed 151
    • Start date changed from estimate of Mar 13, 2026 to Mar 23, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eccogene
4 trials monitored
See 2 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Trial Details
NCT Number NCT07505303
Lead Sponsor Eccogene
Conditions Adult Obesity, Weight Management
Enrollment 151 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov